S&P 500   4,689.60 (+2.13%)
DOW   35,800.60 (+1.63%)
QQQ   396.83 (+2.75%)
AAPL   170.45 (+3.10%)
MSFT   334.67 (+2.60%)
FB   324.73 (+2.16%)
GOOGL   2,932.64 (+2.43%)
AMZN   3,510.77 (+2.43%)
TSLA   1,048.35 (+3.90%)
NVDA   316.72 (+5.44%)
BABA   125.55 (+1.58%)
NIO   33.54 (+3.71%)
CGC   10.80 (+6.40%)
AMD   143.86 (+3.45%)
GE   98.01 (+2.08%)
MU   86.03 (+4.34%)
T   23.13 (-0.64%)
F   19.96 (+3.85%)
DIS   151.35 (+0.65%)
PFE   52.05 (+1.11%)
AMC   30.31 (+5.28%)
ACB   6.29 (+5.36%)
BA   209.47 (+1.74%)
S&P 500   4,689.60 (+2.13%)
DOW   35,800.60 (+1.63%)
QQQ   396.83 (+2.75%)
AAPL   170.45 (+3.10%)
MSFT   334.67 (+2.60%)
FB   324.73 (+2.16%)
GOOGL   2,932.64 (+2.43%)
AMZN   3,510.77 (+2.43%)
TSLA   1,048.35 (+3.90%)
NVDA   316.72 (+5.44%)
BABA   125.55 (+1.58%)
NIO   33.54 (+3.71%)
CGC   10.80 (+6.40%)
AMD   143.86 (+3.45%)
GE   98.01 (+2.08%)
MU   86.03 (+4.34%)
T   23.13 (-0.64%)
F   19.96 (+3.85%)
DIS   151.35 (+0.65%)
PFE   52.05 (+1.11%)
AMC   30.31 (+5.28%)
ACB   6.29 (+5.36%)
BA   209.47 (+1.74%)
S&P 500   4,689.60 (+2.13%)
DOW   35,800.60 (+1.63%)
QQQ   396.83 (+2.75%)
AAPL   170.45 (+3.10%)
MSFT   334.67 (+2.60%)
FB   324.73 (+2.16%)
GOOGL   2,932.64 (+2.43%)
AMZN   3,510.77 (+2.43%)
TSLA   1,048.35 (+3.90%)
NVDA   316.72 (+5.44%)
BABA   125.55 (+1.58%)
NIO   33.54 (+3.71%)
CGC   10.80 (+6.40%)
AMD   143.86 (+3.45%)
GE   98.01 (+2.08%)
MU   86.03 (+4.34%)
T   23.13 (-0.64%)
F   19.96 (+3.85%)
DIS   151.35 (+0.65%)
PFE   52.05 (+1.11%)
AMC   30.31 (+5.28%)
ACB   6.29 (+5.36%)
BA   209.47 (+1.74%)
S&P 500   4,689.60 (+2.13%)
DOW   35,800.60 (+1.63%)
QQQ   396.83 (+2.75%)
AAPL   170.45 (+3.10%)
MSFT   334.67 (+2.60%)
FB   324.73 (+2.16%)
GOOGL   2,932.64 (+2.43%)
AMZN   3,510.77 (+2.43%)
TSLA   1,048.35 (+3.90%)
NVDA   316.72 (+5.44%)
BABA   125.55 (+1.58%)
NIO   33.54 (+3.71%)
CGC   10.80 (+6.40%)
AMD   143.86 (+3.45%)
GE   98.01 (+2.08%)
MU   86.03 (+4.34%)
T   23.13 (-0.64%)
F   19.96 (+3.85%)
DIS   151.35 (+0.65%)
PFE   52.05 (+1.11%)
AMC   30.31 (+5.28%)
ACB   6.29 (+5.36%)
BA   209.47 (+1.74%)
NASDAQ:IONS

Ionis Pharmaceuticals Stock Forecast, Price & News

$29.51
+2.01 (+7.31%)
(As of 12/7/2021 10:44 AM ET)
Add
Compare
Today's Range
$28.67
$30.11
50-Day Range
$25.61
$35.10
52-Week Range
$25.04
$64.37
Volume
28,551 shs
Average Volume
1.24 million shs
Market Capitalization
$4.17 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.91
30 days | 90 days | 365 days | Advanced Chart
Receive IONS News and Ratings via Email

Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Ionis Pharmaceuticals logo

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

Headlines

Ionis Pharmaceuticals (NASDAQ:IONS) Reaches New 52-Week Low at $27.07
November 30, 2021 |  americanbankingnews.com
Ionis Reveals Results study of vupanorsen
November 26, 2021 |  nasdaq.com
Ionis Pharmaceuticals (NASDAQ:IONS) Hits New 1-Year Low at $28.80
November 24, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:IONS
CUSIP
46433010
Employees
757
Year Founded
N/A

Sales & Book Value

Annual Sales
$729 million
Book Value
$3.76 per share

Profitability

Net Income
$-451.29 million
Pretax Margin
-46.01%

Debt

Price-To-Earnings

Miscellaneous

Free Float
137,821,000
Market Cap
$4.17 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/03/2021
Today
12/07/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/23/2022

MarketRank

Overall MarketRank

1.92 out of 5 stars

Medical Sector

723rd out of 1,394 stocks

Pharmaceutical Preparations Industry

342nd out of 673 stocks

Analyst Opinion: 3.2Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions

Is Ionis Pharmaceuticals a buy right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Ionis Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IONS, but not buy additional shares or sell existing shares.
View analyst ratings for Ionis Pharmaceuticals
or view top-rated stocks.

How has Ionis Pharmaceuticals' stock price been impacted by COVID-19?

Ionis Pharmaceuticals' stock was trading at $49.14 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, IONS stock has decreased by 40.0% and is now trading at $29.50.
View which stocks have been most impacted by COVID-19
.

When is Ionis Pharmaceuticals' next earnings date?

Ionis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for Ionis Pharmaceuticals
.

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) posted its quarterly earnings results on Wednesday, November, 3rd. The company reported ($0.58) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.53) by $0.05. The company earned $133 million during the quarter, compared to analyst estimates of $162.01 million. Ionis Pharmaceuticals had a negative net margin of 89.71% and a negative trailing twelve-month return on equity of 89.95%. The business's revenue for the quarter was down 16.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.22) earnings per share.
View Ionis Pharmaceuticals' earnings history
.

What price target have analysts set for IONS?

9 brokers have issued 12-month target prices for Ionis Pharmaceuticals' stock. Their forecasts range from $31.00 to $68.00. On average, they anticipate Ionis Pharmaceuticals' stock price to reach $49.06 in the next year. This suggests a possible upside of 66.3% from the stock's current price.
View analysts' price targets for Ionis Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Ionis Pharmaceuticals' key executives?

Ionis Pharmaceuticals' management team includes the following people:
  • Brett P. Monia, Chief Executive Officer & Director
  • Joel Edwards, Vice President-Corporate & Commercial Operations
  • Elizabeth L. Hougen, Chief Financial Officer & Executive VP-Finance
  • C. Frank Bennett, Chief Scientific Officer & Executive VP
  • Sanjay Bhanot, Chief Medical Officer

What other stocks do shareholders of Ionis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD).

What is Ionis Pharmaceuticals' stock symbol?

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Who are Ionis Pharmaceuticals' major shareholders?

Ionis Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Bellevue Group AG (6.62%), Camber Capital Management LP (1.77%), Geode Capital Management LLC (1.26%), Rockefeller Capital Management L.P. (0.94%), Candriam Luxembourg S.C.A. (0.51%) and Sumitomo Mitsui Trust Holdings Inc. (0.49%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Breaux Castleman, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Frederick T Muto, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke.
View institutional ownership trends for Ionis Pharmaceuticals
.

Which major investors are selling Ionis Pharmaceuticals stock?

IONS stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Renaissance Technologies LLC, Bellevue Group AG, Millennium Management LLC, Invesco Ltd., International Biotechnology Trust PLC, Caption Management LLC, and Two Sigma Advisers LP. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, Eric Swayze, Frederick T Muto, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen, and Stanley T Crooke.
View insider buying and selling activity for Ionis Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Ionis Pharmaceuticals stock?

IONS stock was purchased by a variety of institutional investors in the last quarter, including Camber Capital Management LP, Candriam Luxembourg S.C.A., Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Balyasny Asset Management LLC, Balyasny Asset Management LLC, Squarepoint Ops LLC, and Tudor Investment Corp Et Al.
View insider buying and selling activity for Ionis Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Ionis Pharmaceuticals?

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ionis Pharmaceuticals' stock price today?

One share of IONS stock can currently be purchased for approximately $29.50.

How much money does Ionis Pharmaceuticals make?

Ionis Pharmaceuticals has a market capitalization of $4.17 billion and generates $729 million in revenue each year. The company earns $-451.29 million in net income (profit) each year or ($4.23) on an earnings per share basis.

How many employees does Ionis Pharmaceuticals have?

Ionis Pharmaceuticals employs 757 workers across the globe.

What is Ionis Pharmaceuticals' official website?

The official website for Ionis Pharmaceuticals is www.ionispharma.com.

Where are Ionis Pharmaceuticals' headquarters?

Ionis Pharmaceuticals is headquartered at 2855 GAZELLE COURT, CARLSBAD CA, 92010.

How can I contact Ionis Pharmaceuticals?

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at (760) 931-9200, via email at [email protected], or via fax at 760-603-2700.


This page was last updated on 12/7/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.